Loading
Michelle Xia founded Akeso, the Zhongshan company whose bispecific antibody ivonescimab was the first drug to beat pembrolizumab in a head-to-head trial.
A returnee antibody scientist who founded Akeso in 2012 and built the Tetrabody platform behind cadonilimab (PD-1 x CTLA-4, approved 2022), ivonescimab (PD-1 x VEGF, approved 2024, HARMONi-2 win over pembrolizumab) and penpulimab (FDA approved 2025); licensed ivonescimab's Western rights to Summit Therapeutics for $500 million upfront.
| Title | Journal | Year |
|---|---|---|
| Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors | Journal for ImmunoTherapy of Cancer | 2024 |
| Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity | Journal for ImmunoTherapy of Cancer | 2022 |
| CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors | Cancer Immunology, Immunotherapy | 2024 |
Shares HARMONi-2, Ivonescimab and the tag china.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares HARMONi-A, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.
Shares Cadonilimab, Akeso, Ivonescimab.